Want to see UCBJY full AI Analyst Report?
UCBJY Stock Chart & Stats
$129.21
$0.98(0.71%)
At close: 4:00 PM EDT
$129.21
$0.98(0.71%)
Day’s Range― - ―
52-Week Range$110.76 - $168.70
Previous CloseN/A
Volume40.38K
Average Volume (3M)3.26K
Market Cap
$58.04B
Enterprise Value$61.29B
Total Cash (Recent Filing)$796.67M
Total Debt (Recent Filing)$3.59B
Price to Earnings (P/E)23.6
Beta0.35
Next Earnings
Feb 25, 2027EPS Estimate
3.97Next Dividend Ex-DateN/A
Dividend Yield0.56%
Share Statistics
EPS (TTM)5.81
Shares Outstanding389,011,320
10 Day Avg. Volume0
30 Day Avg. Volume3,258
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)4.16
Price to Sales (P/S)6.08
P/FCF Ratio25.02
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue7.15
Enterprise Value/Gross Profit9.75
Enterprise Value/Ebitda18.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.88
Revenue Forecast (FY)$9.96B
Bulls Say, Bears Say
Bulls Say
Revenue And EBITDA GrowthStrong revenue growth combined with substantial EBITDA expansion indicates meaningful operating leverage and broad commercial execution. If sustained, this earnings improvement can strengthen internal funding for research, support launches, and improve the company’s ability to absorb portfolio transitions.
BIMZELX Commercial MomentumBIMZELX is becoming a major growth platform with expanding geographic reach, patient adoption, and market presence across several indications. Its reiterated peak-sales potential of at least EUR 7bn provides a substantial commercial foundation to offset mature products and support longer-term growth.
Improving Cash GenerationStronger operating and free cash flow improves earnings quality and gives UCB greater capacity to fund R&D, business development, and obligations without relying entirely on external financing. Reasonable recent cash conversion also supports the durability of reported profit, despite some historical fluctuation.
Bears Say
BRIVIACT Exclusivity LossThe expected generic-driven erosion creates a material and identifiable revenue headwind across important markets. Even with growth products expanding, a sharp decline in an established therapy can reduce portfolio stability, complicate comparisons, and require faster replacement through launches and pipeline execution.
Net Price PressureBroader access can support future patient volume, but lower net pricing may dilute near-term revenue quality and margins before the commercial benefit arrives. The absence of repeatable prior-year gross-to-net support adds further pressure, making growth increasingly dependent on sustained volume and mix improvement.
Higher Acquisition-related CostsHigher interest, integration, and corporate expenses can absorb part of the benefit from strong product growth and reduce financial flexibility. The acquisitions may strengthen UCB’s pipeline, but their lasting contribution will depend on successful integration and development progress exceeding these added costs.
UCB SA News
UCBJY FAQ
What was UCB SA’s price range in the past 12 months?
UCB SA lowest stock price was $110.76 and its highest was $168.70 in the past 12 months.
What is UCB SA’s market cap?
UCB SA’s market cap is $58.04B.
When is UCB SA’s upcoming earnings report date?
UCB SA’s upcoming earnings report date is Feb 25, 2027 which is in 122 days.
How were UCB SA’s earnings last quarter?
UCB SA released its earnings results on Jul 30, 2026. The company reported $3.934 earnings per share for the quarter, beating the consensus estimate of $2.909 by $1.025.
Is UCB SA overvalued?
According to Wall Street analysts UCB SA’s price is currently Overvalued.
Does UCB SA pay dividends?
UCB SA pays a Annually dividend of $0.85 which represents an annual dividend yield of 0.56%. See more information on UCB SA dividends here
What is UCB SA’s EPS estimate?
UCB SA’s EPS estimate is 3.97.
How many shares outstanding does UCB SA have?
UCB SA has 389,011,320 shares outstanding.
What happened to UCB SA’s price movement after its last earnings report?
UCB SA reported an EPS of $3.934 in its last earnings report, beating expectations of $2.909. Following the earnings report the stock price went down -12.584%.
Which hedge fund is a major shareholder of UCB SA?
Currently, no hedge funds are holding shares in UCBJY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
UCB SA Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
UCBJY Sentiment 100%
Sector Average 67%
Sector Average 67%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.18%
12-Months-Change
Fundamentals
Return on Equity
19.48%
Trailing 12-Months
Asset Growth
16.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
UCB SA
UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. Its primary product, Cimzia, addresses a spectrum of inflammatory TNF-mediated conditions, encompassing ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For epilepsy management, the company provides Vimpat, Keppra, and Briviact, alongside Nayzilam, an emergency nasal spray for seizure clusters. Neupro is offered for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal alleviate allergy symptoms. The portfolio further extends to Evenity, a treatment for osteoporosis in postmenopausal women, and BIMZELX, used for psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also available for systemic lupus erythematosus. UCB maintains a robust development pipeline featuring therapies such as rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for stereotypic prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Additionally, the company engages in contract manufacturing services. UCB S.A. has forged collaborative agreements with partners including Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. Its operational presence spans the United States, Japan, Germany, a broader European footprint (including Spain, France, Italy, the United Kingdom, and Ireland), China, Belgium, and other global territories. Incorporated in 1925, the company's headquarters are situated in Brussels, Belgium.
UCBJY Company Deck
UCBJY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial performance in H1 2026: robust top-line growth, expanding margins and EBITDA, upgraded guidance, and clear commercial momentum for key growth drivers (notably BIMZELX) alongside meaningful pipeline and strategic acquisitions positioning the company for sustained longer-term growth. Notable risks include BRIVIACT loss of exclusivity with large expected sales declines, anticipated net price pressure from recent access wins (near-term H2 price erosion before volume benefits), increased G&A and integration costs from acquisitions, and competition/heterogeneity risks in HS. On balance, the positive execution, upgraded guidance and attractive pipeline developments outweigh the near-term headwinds.View all UCBJY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors